Tracer library / [177Lu]Lu-177-OPS201

[177Lu]Lu-177-OPS201

Also written as Lu-177-OPS201

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 0

Neuroendocrine neoplasms Dosimetry and biodistribution studies Peptide receptor radionuclide therapy

What it is

Compound class: Somatostatin receptor antagonist peptide (DOTA-conjugated)
Target / mechanism: Somatostatin receptor 2 (SSTR2) antagonist PMID 28450554
Clinical application: SSTR2-expressing tumors (peptide receptor radionuclide therapy) PMID 28450554
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [177Lu]Lu-177-OPS201, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28450554: 'the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2])'. Stage set/updated at stage 39 from PMID 28450554: 'In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) labeled with 177Lu, 90Y, and 111In was compared with the SSTR2 agonist 177Lu-DOTATATE.'.